Stemline Therapeutics (NASDAQ:STML) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06), Fidelity Earnings reports.

NASDAQ:STML opened at $13.20 on Friday. The firm has a market cap of $462.77 million, a P/E ratio of -4.49 and a beta of 0.58. Stemline Therapeutics has a 52-week low of $12.60 and a 52-week high of $20.55.

Several research firms recently issued reports on STML. ValuEngine lowered Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. BidaskClub lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Finally, HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research note on Friday, August 10th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $30.00.

TRADEMARK VIOLATION WARNING: “Stemline Therapeutics (STML) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Recommended Story: Bond

Earnings History for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with's FREE daily email newsletter.